NeuroPace outlines 20%+ CAGR through 2027 as RNS business momentum accelerates
Source: SeekingAlpha
2025-05-13 22:34:17 ET
More on NeuroPace
- NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript
- NeuroPace, Inc. 2025 Q1 - Results - Earnings Call Presentation
- NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
- NeuroPace expects minimal impact of tariffs on its operations and financial results
- Stryker, Boston Scientific down as new tariffs impact medtech industry
Read the full article on Seeking Alpha
For further details see:
NeuroPace outlines 20%+ CAGR through 2027 as RNS business momentum accelerates
Neuropace Inc.
NASDAQ: NPCE
NPCE Trading
0.75% G/L:
$15.495 Last:
70,326 Volume:
$15.35 Open:
NPCE Latest News
April 10, 2026 04:05:00 pm
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceNPCE Stock Data
$508,942,176
26,479,649
0.24%
22
N/A
Medical Equipment & Supplies
Healthcare
US
Mountain View
